A Clinical Study To Compare Shweta Sariva-Hemidesmus Indicus (Linn.) R. Br. And Krishna Sariva- Cryptolepis Buchanani Roem & Schult In The Management Of Mukhdushika (Acne Vulgaris).
试验速览
- 阶段
- 2/3 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 50
- 试验地点
- 1
- 主要终点
- -Efficacy will be checked through the GAGS score and subjective criteria after
研究概览
简要总结
The skin, our largest organ, serves as a crucial barrier against external factors, including pollutants and microbes. Acne vulgaris (Mukhdushika), prevalent among teenagers and adults, affects quality of life significantly. Ayurveda attributes it to vata, kapha, and rakta dosha imbalances, treatable traditionally with vamana and lepana therapies. Modern medicine focuses on pilo-sebaceous unit inflammation and sebum overproduction due to hormonal, bacterial, and allergic triggers. Hemidesmus indicus (Sweta sariva) traditionally aids skin disorders by cooling and detoxifying raktadhatu. However, its overharvesting threatens extinction, prompting exploration of Cryptolepis buchanani (Krishna sariva) as an alternative. This study compares their efficacy in churna and lepa formulations for acne treatment. Cryptolepis buchanani, richly available, may substitute Hemidesmus indicus, enabling sustainable therapeutic practices. This research aims to generate clinical evidence supporting its effectiveness, steering future acne treatments.
研究设计
- 研究类型
- Interventional
- 分配方式
- Coin toss, Lottery, toss of dice, shuffling cards etc
- 盲法
- None
入排标准
- 年龄范围
- 15.00 Year(s) 至 40.00 Year(s)（—）
- 性别
- All
入选标准
- •Voluntary males/females with sign and symptoms of Mukhdushika .
- •Patients from age group of 15-40 years will be selected.
- •No treatment of acne in past 10 days.
- •All skin types (greasy, normal) except sensitive skin.
- •Accepting not to use products with the same end benefits during the entire study duration.
- •Having signed a Consent Form and will be once informed orally and in writing of all information concerning the study procedures and study objectives.
排除标准
- •Patients having dermatological or any other medical problem such as folliculitis and boils or history of allergic dermatitis.
- •Patients using any topical retinoid, topical and systemic steroids, throughout the duration of the study.
- •Patients who are known cases of immune-compromised disease, uncontrolled diabetes, any systemic illness which may interfere with study treatment and procedure.
- •Patients who are known cases of any malignancy.
- •Pregnant and lactating women and patients who are known cases of PCOD or any other gynaecological problems.
- •Any known hypersensitivity to any cosmetic and raw material.
- •Subject in an exclusion period or participating in another similar cosmetic or therapeutic trial.
结局指标
主要结局
-Efficacy will be checked through the GAGS score and subjective criteria after
时间窗: GAGS Score reduced during 30 days of treatment period
treatment period of 30 days.
时间窗: GAGS Score reduced during 30 days of treatment period
次要结局
- Relapsing of the disease will be assessed in the follow up period that is 45th and(60th day of our trial.)
研究者
Kajal Dabas
Institute for Ayurved Studies and Research